NEWTOWN, Pa., Jan. 23, 2020 (GLOBE NEWSWIRE) —Onconova Therapeutics Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that it has regained the…
Lilly and Incyte Announce Top-Line Results from Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine
Study met primary endpoint of at least 75% improvement of skin inflammation Safety profile was consistent with the known safety findings of baricitinib in atopic dermatitis (AD) Study was conducted outside of the U.S. and is the first and only…
Bayer gets Japanese approval for prostate cancer drug Nubeqa
Bayer and Orion’s prostate cancer drug Nubeqa (darolutamide) is gaining steam in its battle against rivals from J&J and Pfizer/Astellas as Japan becomes the latest country to approve the drug. The Japanese Ministry of Health, Labor and Welfare (MHLW) has…
AstraZeneca Commits to Zero Carbon Emissions by 2025
With the world watching at the World Economic Forum in Switzerland, AstraZeneca announced a bold plan to have zero carbon emissions from its global operations within the next five years. That would accelerate the company’s “decarbonization” plan by more than…
Eisai: Approval of Antiepileptic Drug Fycompa in Japan for Monotherapy and Pediatric Indications for Partial-Onset Seizures, as well as a New Formulation
TOKYO, Jan 23, 2020 – (JCN Newswire) – Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-house developed antiepileptic drug (AED) Fycompa (perampanel) for an additional indication for monotherapy of partial-onset seizures…
Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor
One year ago, Takeda wrapped up its acquisition of Shire plc, which created one of the largest drug developers focused on rare diseases. Over the past year, the company strived to transform itself into becoming a frontrunner in multiple areas,…
Horizon Therapeutics Wins FDA Approval for First Thyroid Eye Disease Treatment
Ireland’s Horizon Therapeutics became the first to win regulatory approval in the United States for the treatment of Thyroid Eye Diseases, a progressive autoimmune disorder that can threaten the vision of those afflicted. Tuesday afternoon the U.S. Food and Drug…
KT and Samsung Medical Center to Build 5G Smart Hospital
World’s First Application of 5G Technology in Medical Practice Sync Cams Share Real-Time HD Video Footage of Surgery for Teaching 5G Network Base Made Secure for Medical Service Development Enterprise-Dedicated 5G Network Protects Private Medical Info from Hacking SEOUL, South…
TenNor Therapeutics Received FDA Orphan Drug Designation
SUZHOU, China, Jan. 20, 2020 /PRNewswire/ — TenNor Therapeutics, a clinical-stage, global biopharmaceutical company has received FDA Orphan Drug Designation for TNP-2092 to treat prosthetic joint infections. Medical devices such as prosthetic joints, central venous catheters and artificial heart valves…
ResMed Introduces AirFit F30i, Its First Tube-up Full Face CPAP Mask
SAN DIEGO–(BUSINESS WIRE)– ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit F30i, its first tube-up full face CPAP mask, rounding out the most complete full face mask portfolio on the market. This press release features multimedia. View the full release…
